These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 26804741)
1. Novel Strategies for the Treatment of Pseudomonas aeruginosa Infections. Wagner S; Sommer R; Hinsberger S; Lu C; Hartmann RW; Empting M; Titz A J Med Chem; 2016 Jul; 59(13):5929-69. PubMed ID: 26804741 [TBL] [Abstract][Full Text] [Related]
2. Targeting quorum sensing in Pseudomonas aeruginosa biofilms: current and emerging inhibitors. Jakobsen TH; Bjarnsholt T; Jensen PØ; Givskov M; Høiby N Future Microbiol; 2013 Jul; 8(7):901-21. PubMed ID: 23841636 [TBL] [Abstract][Full Text] [Related]
3. Application of Dual Inhibition Concept within Looped Autoregulatory Systems toward Antivirulence Agents against Pseudomonas aeruginosa Infections. Thomann A; de Mello Martins AG; Brengel C; Empting M; Hartmann RW ACS Chem Biol; 2016 May; 11(5):1279-86. PubMed ID: 26882081 [TBL] [Abstract][Full Text] [Related]
4. Baicalin inhibits biofilm formation, attenuates the quorum sensing-controlled virulence and enhances Pseudomonas aeruginosa clearance in a mouse peritoneal implant infection model. Luo J; Dong B; Wang K; Cai S; Liu T; Cheng X; Lei D; Chen Y; Li Y; Kong J; Chen Y PLoS One; 2017; 12(4):e0176883. PubMed ID: 28453568 [TBL] [Abstract][Full Text] [Related]
5. Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor. Furiga A; Lajoie B; El Hage S; Baziard G; Roques C Antimicrob Agents Chemother; 2015 Dec; 60(3):1676-86. PubMed ID: 26711774 [TBL] [Abstract][Full Text] [Related]
6. Central role of quorum sensing in regulating the production of pathogenicity factors in Pseudomonas aeruginosa. Girard G; Bloemberg GV Future Microbiol; 2008 Feb; 3(1):97-106. PubMed ID: 18230038 [TBL] [Abstract][Full Text] [Related]
7. Bioavailability-enhanced Resveramax™ modulates quorum sensing and inhibits biofilm formation in Pseudomonas aeruginosa PAO1. Vasavi HS; Sudeep HV; Lingaraju HB; Shyam Prasad K Microb Pathog; 2017 Mar; 104():64-71. PubMed ID: 28065820 [TBL] [Abstract][Full Text] [Related]
8. High-Throughput Approaches for the Identification of Kang D; Zhang L; Kirienko NV mBio; 2021 May; 12(3):. PubMed ID: 33947765 [TBL] [Abstract][Full Text] [Related]
10. [Foreign body infections--biofilms and quorum sensing]. Høiby N; Johansen HK; Ciofu O; Jensen PØ; Bjarnsholt T; Givskov M Ugeskr Laeger; 2007 Nov; 169(48):4163-6. PubMed ID: 18211783 [TBL] [Abstract][Full Text] [Related]
11. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Pang Z; Raudonis R; Glick BR; Lin TJ; Cheng Z Biotechnol Adv; 2019; 37(1):177-192. PubMed ID: 30500353 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant effect of cranberry proanthocyanidin active fraction on antivirulent property of ciprofloxacin against Pseudomonas aeruginosa. Vadekeetil A; Alexandar V; Chhibber S; Harjai K Microb Pathog; 2016 Jan; 90():98-103. PubMed ID: 26620081 [TBL] [Abstract][Full Text] [Related]
13. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors. Nafee N; Husari A; Maurer CK; Lu C; de Rossi C; Steinbach A; Hartmann RW; Lehr CM; Schneider M J Control Release; 2014 Oct; 192():131-40. PubMed ID: 24997276 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of 4-(alkyloxy)-6-methyl-2H-pyran-2-one derivatives as quorum sensing inhibitors. Park S; Kim HS; Ok K; Kim Y; Park HD; Byun Y Bioorg Med Chem Lett; 2015 Aug; 25(15):2913-7. PubMed ID: 26048802 [TBL] [Abstract][Full Text] [Related]
15. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. Ciofu O; Tolker-Nielsen T; Jensen PØ; Wang H; Høiby N Adv Drug Deliv Rev; 2015 May; 85():7-23. PubMed ID: 25477303 [TBL] [Abstract][Full Text] [Related]
16. Novel therapeutic strategies to counter Pseudomonas aeruginosa infections. Fothergill JL; Winstanley C; James CE Expert Rev Anti Infect Ther; 2012 Feb; 10(2):219-35. PubMed ID: 22339195 [TBL] [Abstract][Full Text] [Related]
17. Pseudomonas aeruginosa: targeting cell-wall metabolism for new antibacterial discovery and development. Lamers RP; Burrows LL Future Med Chem; 2016 Jun; 8(9):975-92. PubMed ID: 27228070 [TBL] [Abstract][Full Text] [Related]
18. Review: Antibiotic discovery in the age of structural biology - a comprehensive overview with special reference to development of drugs for the treatment of Pseudomonas aeruginosa infection. Koehnke A; Friedrich RE In Vivo; 2015; 29(2):161-7. PubMed ID: 25792642 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of Pseudomonas aeruginosa by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers. Howard JJ; Sturge CR; Moustafa DA; Daly SM; Marshall-Batty KR; Felder CF; Zamora D; Yabe-Gill M; Labandeira-Rey M; Bailey SM; Wong M; Goldberg JB; Geller BL; Greenberg DE Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137807 [No Abstract] [Full Text] [Related]
20. Small molecule disruption of quorum sensing cross-regulation in pseudomonas aeruginosa causes major and unexpected alterations to virulence phenotypes. Welsh MA; Eibergen NR; Moore JD; Blackwell HE J Am Chem Soc; 2015 Feb; 137(4):1510-9. PubMed ID: 25574853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]